Legend: CC = Colorado Convention Center H = Hyatt Regency Denver at Colorado Convention Center
Activity Details
342 *
Tue, 7/30/2019,
10:30 AM -
12:20 PM
CC-109
Topics in Adaptive-Seamless and Group Sequential Designs — Contributed Papers
Biopharmaceutical Section
Chair(s): Qi Jiang, Seattle Genetics
10:35 AM
Adaptive Sequential Design for Seamless Phase 2/3 Combination
Ping Gao, Brightech International ; Tai Xie, Brightech International; Peng Zhang, Brightech International; Yue Tu, Brightech International; Lingyun Liu, Cytel; Cyrus Mehta, Cytel
10:50 AM
Selecting Critical Boundaries in Group-Sequential Trials with Multiple Endpoints
Toshimitsu Hamasaki, National Cerebral and Cardiovascular Center ; Hsien-Ming James Hung, PhD, Food and Drug Administration; Chin-Fu Hsiao, National Health Research Institutes; Scott R Evans, George Washington University
11:05 AM
Covariate Adaptive Randomization in Seamless Phase II/III Clinical Trials
Hongjian Zhu, University of Texas Health Science Center at Houston ; Wei Ma, Renmin University; Mengxi Wang, University of Texas Health Science Center at Houston
11:20 AM
Evaluation of Type 1 Error in a 2-In-1 Adaptive Phase 2/3 Design with Dual-Primary Endpoints in Oncology Studies
Li Fan, Merck ; Jing Zhao, Merck Research Labs
11:35 AM
Implementation of an Adaptive Early Phase Trial Design for Drug Combinations
Bethany Horton, University of Virginia ; Nolan Wages, University of Virginia
11:50 AM
Developing Innovative Group Sequential Design Trials That Account for the Correlation Between Test Statistics
JonDavid Sparks, Eli Lilly & Company ; Bill Prucka, Eli Lilly & Company; Brian Millen, Eli Lilly & Company
12:05 PM
Unblinded Sample Size Re-Estimation in Clinical Trials with Count Outcomes
Yeting Du, Cytel Inc ; Lingyun Liu, Cytel
